Shots:
- Polpharma has reported that its JV company, Bioeq has submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA. FYB201 was originally licensed from Formycon AG
- The launch of biosimilar ranibizumab may increase market competition, reduce cost and expand patient access with proven analytical & clinical similarity to Lucentis
- Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases including wet AMD, DR, macular edemas and MCNV. If approved, Coherus will commercialize FYB201 in the US
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar, ranibizumab) first appeared on PharmaShots.
